NovaBay Pharmaceuticals Signs Agreement With Nation's Second Largest Independent Optometry Group, AllDocs
The agreement will bring NovaBay's innovative eyelid and lash hygiene product Avenova to hundreds of additional optometry offices including LensCrafters
EMERYVILLE, CA / CRWEPRESSRELEASE / September 16, 2015 /NovaBay(R) Pharmaceuticals, Inc. (NYSEMKT:NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced that the company’s prescription daily eyelid and lash hygiene product Avenova(TM) will be marketed through ALLDocs Optometry Group, making the product available to the group's optometrists.
AllDocs, also known as The Association of LensCrafters Leaseholding Doctors, is the second largest independent optometry group in the U.S. It works closely with its LensCrafters partners.
"This agreement with ALLDocs will bring Avenova to hundreds of additional optometrists and thousands of additional patients," said Glenn Moro, VP Sales & Marketing for Avenova at NovaBay. "It also demonstrates how demand for Avenova is growing among optometrists as they learn about the many benefits the product brings to patients."
Combined with NovaBay's previous distribution agreements with McKesson Corporation (NYSE: MCK), Cardinal Health (NYSE: CAH), AmerisourceBergen and Vision Source, the largest independent optometry network in the U.S. , the new agreement means that Avenova now will be available in thousands of optometrist and ophthalmologist offices across the country, in addition to the majority of the nation's 67,000 pharmacies and many retail chains.
"This agreement certainly has the potential to increase Avenova sales," said Ron Najafi, Ph.D., President and CEO of NovaBay. "More importantly, the impact of the agreement will be that more patients suffering from chronic and often-painful eye conditions like blepharitis will finally be able to find relief."
Avenova is the only lid hygiene product that contains Neutrox(TM), NovaBay's proprietary pure hypochlorous acid, which mimics a naturally occurring substance produced by white blood cells to fight microbial invaders. Lab tests show that Neutrox is effective in solution both at killing microbes and at neutralizing bacterial enzymes and toxins. Those properties enable Avenova to help in the management of blepharitis and other common eye conditions like meibomian gland dysfunction.Indeed, both patients and doctors report that a regimen of daily lid hygiene using Avenova has been remarkably successful in managing those conditions.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical eye care market with its two distinct product categories: the NEUTROX(TM) Family of Products, cleared by the US FDA as a 510(k) medical device; the NEUTROX(TM) Family of Products includes AVENOVA(TM) for the eye care market and NEUTROPHASE(R) for wound care, and CELLERX(TM) for the cosmetic surgery and aesthetic dermatology market; and its AGANOCIDE(R) compounds, led by AURICLOSENE(TM)which is in development as a new drug in urology and dermatology.
NovaBay has partnerships in the U.S. and around the world with PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and the Middle East), Sarmedic Ltd (Israel), Ophthalmic Instrument Company (New Zealand) and Alpha Pharma LLC (the Ukraine).
In June 2015 NovaBay announced FDA clearance of intelli-Case(TM), an innovative, easy-to-use device for safely disinfecting soft and rigid gas permeable (RGP) contact lenses with hydrogen peroxide.
This press release contains "forward-looking statements." Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Stay informed on NovaBay's progress:
From the Company
Thomas J. Paulson
Chief Financial Officer
For Partnership Purposes
SVP Business Development
SOURCE:NovaBay Pharmaceuticals, Inc.